DK1095654T3 - Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose - Google Patents

Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose

Info

Publication number
DK1095654T3
DK1095654T3 DK01200197T DK01200197T DK1095654T3 DK 1095654 T3 DK1095654 T3 DK 1095654T3 DK 01200197 T DK01200197 T DK 01200197T DK 01200197 T DK01200197 T DK 01200197T DK 1095654 T3 DK1095654 T3 DK 1095654T3
Authority
DK
Denmark
Prior art keywords
medicament
raloxifene
atherosclerosis
analogues
manufacture
Prior art date
Application number
DK01200197T
Other languages
Danish (da)
English (en)
Inventor
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1095654T3 publication Critical patent/DK1095654T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Semiconductor Lasers (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Finger-Pressure Massage (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01200197T 1993-12-21 1994-12-19 Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose DK1095654T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17060693A 1993-12-21 1993-12-21

Publications (1)

Publication Number Publication Date
DK1095654T3 true DK1095654T3 (da) 2004-03-15

Family

ID=22620568

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01200197T DK1095654T3 (da) 1993-12-21 1994-12-19 Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose
DK94309461T DK0664121T3 (da) 1993-12-21 1994-12-19 Anvendelse af raloxifen og dets analoger til fremstilling af et medikament til behandling af aterosclerose og iskæmisk hjertesygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94309461T DK0664121T3 (da) 1993-12-21 1994-12-19 Anvendelse af raloxifen og dets analoger til fremstilling af et medikament til behandling af aterosclerose og iskæmisk hjertesygdom

Country Status (20)

Country Link
EP (3) EP1095654B1 (cs)
JP (1) JPH07196498A (cs)
KR (1) KR950016722A (cs)
CN (1) CN1095663C (cs)
AT (3) ATE254459T1 (cs)
AU (1) AU698389B2 (cs)
CA (1) CA2138508A1 (cs)
CZ (1) CZ286365B6 (cs)
DE (3) DE69428882T2 (cs)
DK (2) DK1095654T3 (cs)
ES (3) ES2215270T3 (cs)
HU (1) HUT71476A (cs)
IL (1) IL112034A (cs)
NO (1) NO313083B1 (cs)
NZ (1) NZ270162A (cs)
PT (3) PT664121E (cs)
RU (1) RU2127592C1 (cs)
TW (1) TW427902B (cs)
UA (1) UA39941C2 (cs)
ZA (1) ZA9410091B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
US6545027B1 (en) 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
DE69622472T2 (de) * 1995-06-07 2003-02-06 Eli Lilly And Co., Indianapolis Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
KR100478181B1 (ko) 1998-08-24 2005-03-23 토카이 유니버시티 에듀케이셔널시스템 카르보닐 스트레스상태 개선제 및 복막투석액
RU2464794C1 (ru) * 2011-10-25 2012-10-27 Канапья Табылдыевич Шагиев Состав для производства кисломолочного продукта "курт"
CN103768601A (zh) * 2012-10-22 2014-05-07 中国科学院上海生命科学研究院 抑制micro-RNA155用于预防和治疗动脉粥样硬化的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) * 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol

Also Published As

Publication number Publication date
PT1095654E (pt) 2004-04-30
KR950016722A (ko) 1995-07-20
DE69433348D1 (de) 2003-12-24
ATE254459T1 (de) 2003-12-15
DE69433578D1 (de) 2004-04-01
IL112034A0 (en) 1995-03-15
AU8156394A (en) 1995-06-29
IL112034A (en) 1999-03-12
DE69433578T2 (de) 2004-12-16
CZ320494A3 (en) 1995-09-13
ATE260104T1 (de) 2004-03-15
DE69433348T2 (de) 2004-08-26
EP0664121B1 (en) 2001-10-31
DE69428882T2 (de) 2002-04-25
EP1095654A2 (en) 2001-05-02
EP0963756A3 (en) 1999-12-22
ES2215270T3 (es) 2004-10-01
AU698389B2 (en) 1998-10-29
EP1095654A3 (en) 2001-06-13
DE69428882D1 (de) 2001-12-06
NZ270162A (en) 1997-06-24
NO944913L (no) 1995-06-22
NO944913D0 (no) 1994-12-19
JPH07196498A (ja) 1995-08-01
CN1108090A (zh) 1995-09-13
RU2127592C1 (ru) 1999-03-20
RU94045270A (ru) 1996-10-20
ATE207749T1 (de) 2001-11-15
DK0664121T3 (da) 2001-12-03
NO313083B1 (no) 2002-08-12
CN1095663C (zh) 2002-12-11
EP0963756A2 (en) 1999-12-15
CZ286365B6 (cs) 2000-03-15
EP0963756B1 (en) 2004-02-25
UA39941C2 (uk) 2001-07-16
PT664121E (pt) 2002-03-28
TW427902B (en) 2001-04-01
ES2163425T3 (es) 2002-02-01
ZA9410091B (en) 1996-06-19
HUT71476A (en) 1995-11-28
ES2210089T3 (es) 2004-07-01
EP0664121A1 (en) 1995-07-26
HU9403660D0 (en) 1995-02-28
PT963756E (pt) 2004-06-30
EP1095654B1 (en) 2003-11-19
CA2138508A1 (en) 1995-06-22

Similar Documents

Publication Publication Date Title
DK1095654T3 (da) Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
ES2157957T3 (es) Procedimientos para inhibir la endometriosis.
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
DK0659416T3 (da) Inhibering af seborE og acne
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
DK0652004T3 (da) Fremgangsmåder til behandling af resistente neoplasmer
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO944577L (no) Hemming av effekten av amyloidogene proteiner
NO20000750D0 (no) Fremgangsmåte for å redusere blodplatetall
GR3002594T3 (en) Aromatic thioethers